Skip to main content

Table 2 mRNA expression of 76 mitotic-spindle-checkpoint genes in invasive breast tumors relative to normal breast tissues

From: Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy

Genes Normal breast tissues
(n = 5)
Invasive breast tumors
(n = 10)
pa
NEK2 1.0 (0.44-2.23) 28.79 (7.41-162.02) b < 0.01
UBD 1.0 (0.31-1.91) 16.95 (1.38-42.32) < 0.01
TPX2 1.0 (0.59-1.48) 13.01 (5.51-144.34) < 0.01
CENPE 1.0 (0.02-2.06) 11.01 (2.41-42.62) < 0.01
CCNB2 1.0 (0.64-1.95) 10.36 (3.14-73.18) < 0.01
BIRC5 1.0 (0.37-2.00) 9.45 (3.64-136.55) < 0.01
NCD80 1.0 (0.29-1.23) 9.24 (2.08-114.83) < 0.01
BUB1 1.0 (0.53-1.51) 8.52 (2.22-58.49) < 0.01
CCNA2 1.0 (0.56-1.90) 8.08 (4.10-52.35) < 0.01
CDC2 1.0 (0.68-1.66) 7.62 (2.59-44.74) < 0.01
BUB1B 1.0 (0.53-1.69) 7.44 (2.47-35.02) < 0.01
TTK 1.0 (0.71-2.08) 6.47 (1.27-36.76) < 0.01
AURKB 1.0 (0.90-2.08) 5.56 (2.02-81.20) < 0.01
PLK1 1.0 (0.60-1.87) 5.52 (2.72-44.53) < 0.01
AURKA 1.0 (0.36-1.33) 4.76 (3.00-39.85) < 0.01
TACC3 1.0 (0.54-2.08) 4.70 (1.73-21.06) < 0.01
CCNB3 1.0 (0.96-4.20) 4.62 (0.80-39.31) < 0.05
ZWINT 1.0 (0.62-1.97) 4.28 (1.78-21.76) < 0.01
CCNB1 1.0 (0.42-2.32) 4.03 (1.10-15.63) < 0.01
CDC20 1.0 (0.61-1.28) 3.51 (0.89-21.21) < 0.05
PRCC 1.0 (0.70-1.27) 2.70 (2.27-4.87) < 0.01
CDKN1A 1.0 (0.61-2.57) 2.43 (1.04-5.59) < 0.05
RAN 1.0 (0.59-1.92) 2.42 (1.23-6.57) < 0.01
ESPL1 1.0 (0.34-1.85) 2.27 (1.23-8.79) < 0.05
PTTG1 1.0 (0.82-1.35) 2.25 (1.61-11.24) < 0.01
KNTC1 1.0 (0.71-1.30) 2.21 (0.80-4.83) < 0.05
BRCA2 1.0 (0.70-1.41) 2.17 (0.68-5.86) < 0.05
RAE1 1.0 (0.81-1.48) 2.16 (1.37-3.48) < 0.01
MAD2L1 1.0 (0.65-1.30) 2.11 (1.16-5.25) < 0.01
AURKAIP1 1.0 (0.94-1.59) 1.96 (1.30-4.68) < 0.01
PPP1CA 1.0 (0.65-1.55) 1.95 (1.47-3.31) < 0.01
BUB3 1.0 (0.65-1.20) 1.87 (1.27-5.64) < 0.01
ANAPC7 1.0 (0.61-1.32) 1.77 (1.59-2.36) < 0.01
CDC27 1.0 (0.57-1.36) 1.67 (1.19-2.32) < 0.01
ZWILCH 1.0 (0.88-1.33) 1.63 (0.75-3.93) < 0.05
PPP1R2 1.0 (067-1.18) 1.55 (0.81-2.06) < 0.05
MAD2L2 1.0 (0.37-1.20) 1.45 (0.69-7.28) < 0.05
UBE1C 1.0 (0.84-1.03) 1.40 (1.07-1.93) < 0.01
UBE2N 1.0 (0.77-1.09) 1.31 (1.29-2.83) < 0.01
CDC23 1.0 (0.71-1.18) 1.21 (0.79-1.53) < 0.05
SMC1B 1.0 (0.43-1.81) 2.89 (0.07-10.65) NS
HSPB1 1.0 (0.66-1.47) 2.03 (0.66-6.79) NS
TACC2 1.0 (0.94-2.30) 1.70 (0.69-4.27) NS
ANAPC11 1.0 (0.13-2.41) 1.65 (0.80-3.95) NS
CSE1L 1.0 (0.61-1.23) 1.59 (0.75-3.87) NS
RAD21 1.0 (0.71-1.17) 1.58 (0.57-8.38) NS
SMC3 1.0 (0.71-1.45) 1.56 (0.59-3.26) NS
RCC1 1.0 (0.39-1.68) 1.54 (0.87-3.75) NS
FBXO5 1.0 (0.42-1.35) 1.50 (0.65-4.52) NS
BRCA1 1.0 (0.75-1.29) 1.37 (0.58-5.67) NS
ANAPC10 1.0 (0.56-1.65) 1.34 (0.88-1.75) NS
CEP250 1.0 (0.87-1.54) 1.33 (0.88-3.08) NS
RNF2 1.0 (0.96-1.13) 1.33 (0.64-2.88) NS
CDC34 1.0 (0.33-1.52) 1.23 (0.63-1.97) NS
ANAPC1 1.0 (0.75-1.43) 1.22 (0.54-1.59) NS
SMC1A 1.0 (0.67-1.05) 1.09 (0.56-1.98) NS
UBE2B 1.0 (0.72-1.77) 1.09 (0.41-2.11) NS
NEDD8 1.0 (0.34-1.61) 1.08 (0.30-2.13) NS
ANAPC5 1.0 (0.61-1.13) 1.07 (0.94-1.34) NS
ZW10 1.0 (0.39-1.01) 1.07 (0.63-3.39) NS
STAG2 1.0 (0.76-2.53) 1.05 (0.33-2.15) NS
CDC16 1.0 (0.66-1.19) 0.99 (0.57-1.52) NS
CLAPS2 1.0 (0.84-1.31) 0.98 (0.61-1.74) NS
CDC26 1.0 (0.46-1.41) 0.97 (0.61-1.53) NS
CLASP1 1.0 (0.84-1.54) 0.93 (0.71-1.45) NS
CCNA1 1.0 (0.28-1.06) 0.84 (0.41-3.69) NS
MAD1L1 1.0 (0.37-1.13) 0.69 (0.42-1.12) NS
TACC1 1.0 (0.92-2.06) 0.78 (0.63-1.33) < 0.05
ANAPC2 1.0 (0.40-1.23) 0.77 (0.62-1.45) < 0.05
FZR1 1.0 (0.40-1.29) 0.73 (0.51-1.18) < 0.05
STAG1 1.0 (0.68-1.14) 0.69 (0.36-1.00) < 0.05
ANAPC4 1.0 (0.52-1.10) 0.68 (0.43-1.08) < 0.05
MRE11A 1.0 (0.90-1.23) 0.64 (0.26-1.23) < 0.05
FBXW7 1.0 (0.84-1.29) 0.56 (0.41-1.14) < 0.05
AURKC 1.0 (0.63-1.43) 0.49 (0.34-2.66) < 0.05
RASSF1 1.0 (0.17-3.10) 0.44 (0.12-1.68) < 0.05
  1. aMann and Whitney's U Test
  2. bMedian (range) of gene mRNA levels. The mRNA levels of the tumor samples were normalized such that the median of the 5 normal breast tissues mRNA levels was 1.